Saturday, April 28, 2012

FDA approves Vivus's fast-acting Viagra rival

NEW YORK (Reuters) -

Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus Inc won U.S. approval for avanafil, its faster acting rival to Viagra.

Avanafil, which will be sold under the brand name Stendra, is the first new drug in the category in a decade.

While it is recommended that patients take the new pill 30 minutes prior to sexual activity, in clinical trials it has been shown to work in as fast as 15 minutes. Viagra typically takes about an hour to start working.

The most common side effects reported in clinical studies included headache, flushing of the face and other areas, nasal congestion, common cold-like symptoms and back pain.

Read the full Reuters Health report:   
 FDA approves Vivus's fast-acting Viagra rival

Wednesday, April 18, 2012

Pricier therapy no better for early prostate cancer

NEW YORK (Reuters Health) -

A new study suggests that expensive, high-tech proton beam radiation doesn't do any more for men with prostate cancer than the most commonly-used option.

Proton beam radiation, heavily promoted by facilities that perform the treatment, also came with a higher risk of certain side effects compared to intensity-modulated radiation therapy (IMRT), researchers found.


The findings suggest that men have multiple radiation options when it comes to treating early, localized prostate cancer.
Though not covered in the new study, their options also include surgery -- or getting no treatment at all and waiting to see how the disease progresses, researchers said.

Read the full Reuters Health report: 
Pricier therapy no better for early prostate cancer

Saturday, April 14, 2012

Prostate & Baldness drugs may have sexual side effects

Merck drugs Propecia and Proscar will get new labels detailing possible sexual side effectsTwo Merck drugs for treating male baldness and enlarged prostate will now carry extended labels to add more possible sexual side effects, US regulators said on Friday.

The changes involve Propecia and Proscar, both of which contain the active ingredient finasteride

The new Propecia label will include "libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug," the FDA said. Propecia is a drug to treat male baldness.
Proscar, which treats symptoms of enlarged prostate, will now have a label that adds "decreased libido that continued after discontinuation of the drug."
In addition, both labels are being revised to "include a description of reports of male infertility and/or poor semen quality that normalized or improved after drug discontinuation," the FDA said.


Read the full story here:
US warns two drugs may have sexual side effects

Tuesday, April 10, 2012

Researchers Find Genes Linked to Aggressive Prostate Cancer

MONDAY, April 9 (HealthDay News)

The discovery of two inherited genetic variations may help doctors identify men at greater risk for aggressive prostate cancer, a new study suggests.

A man's risk for the disease could triple or even quadruple depending on the genetic variant they have, according to the researchers from Weill Cornell Medical College in New York City and elsewhere.

Having a family history of prostate cancer is the strongest risk factor for the disease. As a result, the researchers set out to find DNA that is deleted or duplicated in the genetic information of men with prostate cancer compared to those who do not have the disease.

In testing the effect of the two inherited variants in a lab, the investigators showed that the variants helped cancer cells grow and invade, putting some men at four times greater risk for prostate cancer.

 Read the full HealthDay News report here:
 Researchers Find Genes Linked to Aggressive Prostate Cancer:

Friday, March 30, 2012

Circumcision Hype?

 A new study linking circumcision before sexual intercourse to lower rates of prostate cancer may be so flawed that the conclusions are meaningless, says Dr. Gerald Chodak.
Medscape Urology

Read the Medscape report here:
Circumcision Hype?

Thursday, March 29, 2012

Self-checking won't spot testicle cancer

'There is no good evidence that routine testicular self-examination is of any benefit, says doctorCelebrity appeals for British men to check their testicles to detect early signs of cancer are a waste of time and possibly harmful, an opinion piece published by the British Medical Journal (BMJ) says.

Read the report here:
Self-checking won't spot testicle cancer

Monday, March 12, 2012

Circumcision tied to lower prostate cancer risk

NEW YORK (Reuters Health) - Circumcised men may have a slightly lower risk of developing prostate cancer than those who still have their foreskin, according to a new study.

The new work falls short of actually proving that removing a boy's foreskin will cut his future cancer risk, said Dr. Jonathan L. Wright, who led the research.

"I would not go out and advocate for widespread circumcision to prevent prostate cancer," Wright, of the Fred Hutchinson Cancer Research Center in Seattle, told Reuters Health."We see an association, but it doesn't prove causality." 



Read the full Reuters Health report:
Circumcision tied to lower prostate cancer risk